This inventor holds 1 USPTO granted patent and 6 published patent applications. Top assignee: Jiangsu Nuo-Beta Pharmaceutical Technology Co. Ltd.. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Le Zhang: Innovator in Alzheimer's Disease Research
Introduction
Le Zhang is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of Alzheimer's disease research. His innovative approaches aim to improve the understanding and treatment of this complex condition.
Latest Patents
Le Zhang holds a patent for the "Application of PI4KIIIA protein and related membrane protein complex in treating Alzheimer's disease." This patent describes a genetic method to down-regulate specific proteins, which can reduce the accumulation of Aβ within neurons. The method also addresses age-dependent synaptic transmission failure in a fruit fly Alzheimer's disease model. Furthermore, it provides a way to improve learning and memory abilities in Alzheimer's model mice. The patent outlines methods for using inhibitors to treat Alzheimer's disease and for screening drugs that promote Aβ secretion by nerve cells.
Career Highlights
Le Zhang is associated with Jiangsu Nuo-beta Pharmaceutical Technology Co. Ltd. His work focuses on innovative solutions for treating Alzheimer's disease, showcasing his commitment to advancing medical research. His contributions have the potential to impact the lives of many individuals affected by this condition.
Collaborations
Le Zhang collaborates with notable colleagues, including Fude Huang and Xiao Xun Zhang. Their combined expertise enhances the research efforts in the field of Alzheimer's disease.
Conclusion
Le Zhang's innovative work in Alzheimer's disease research highlights the importance of scientific advancements in addressing complex health challenges. His contributions through patents and collaborations pave the way for future breakthroughs in treatment options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile